RAW Labs SA is a biomedical-technology development company based at the Biopole of Lausanne, Switzerland. The company focuses on bringing early-stage biomedical technologies, including therapeutics and diagnostics, developed in research institutes to the attention of the pharmaceutical industry. Their portfolio includes critical care products designed to combat sepsis and treat severe bacterial and viral infections. One of their key products, CAL02, is a first-in-class anti-virulence agent aimed at treating severe pneumonia by neutralizing virulence effectors that contribute to organ failure and fatal complications in severe infections. RAW Labs SA's innovative approach and cutting-edge technologies have the potential to significantly impact the field of biomedical research and healthcare.
Melanie Blokesch, Nicolas Jean Philippe Guex, Christian Iseli, Alexandre Lemopoulos, Nina Vesel
Sandor Kasas, María Inés Villalba
Martin Jaggi, Mary-Anne Hartley, Juliane Dervaux, Tatjana Chavdarova, Daniel Mueller, Julien Niklas Heitmann, Daniel Hinjos García